

REMARKS

Claims 1, 3, 6-12, 14, 16-20, 22-31, and 33-55 are currently pending. Claims 2, 4-5, 13, 15, 21, and 32 were previously canceled. In the Office Action, the Examiner required restriction to one of the following groups of claims:

Group 1, claims 1, 3, 6-8, 30, 31, and 33-46, drawn to methods of delivering a biologically active molecule to a cell comprising contacting the cell with a polyplex formed from an interaction between a biologically active molecule and a cellular delivery polymer that is a polyhydroxylamidoamine.

Group 2, claims 1, 3, 6-8, 30, 31, and 47-50, drawn to methods of delivering a biologically active molecule to a cell comprising contacting the cell with a polyplex formed from an interaction between a biologically active molecule and a cellular delivery polymer that is a cyclodextrin-based dendritic macromolecule.

Group 3, claims 1, 3, 6-8, 30, 31, and 51-53, drawn to methods of delivering a biologically active molecule to a cell comprising contacting the cell with a polyplex formed from an interaction between a biologically active molecule and a cellular delivery polymer that is a 1,3-dipolar addition polymer.

Group 4, claims 1, 3, 6-8, 30, 31, 54 and 55, drawn to methods of delivering a biologically active molecule to a cell comprising contacting the cell with a polyplex formed from an interaction between a biologically active molecule and a cellular delivery polymer that is a carbohydrate-containing biodegradable polyester.

Group 5, claims 9-12, 14, 16-20, and 22-29, drawn to a composition comprising a biologically active molecule and a cellular delivery polymer that is a polyhydroxylamidoamine.

Group 6, claims 9-12, 14, 16-20, and 22-29, drawn to a composition comprising a biologically active molecule and a cellular delivery polymer that is a cyclodextrin-based dendritic macromolecule.

Group 7, claims 9-12, 14, 16-20, and 22-29, drawn to a composition comprising a biologically active molecule and a cellular delivery polymer that is a 1,3-dipolar addition polymer.

Group 8, claims 9-12, 14, 16-20, and 22-29, drawn to a composition comprising a biologically active molecule and a cellular delivery polymer that is a carbohydrate-containing biodegradable polyester.

Without commenting on the merits of the restriction requirement, and in the interest of expediting prosecution, Applicant hereby elects, without traverse, Group 5, including claims 9-12, 14, 16-20, and 22-29, drawn to a composition comprising a biologically active molecule and a cellular delivery polymer that is a polyhydroxylamidoamine.

CONCLUSION

It is believed that the above represents a complete response to the Office Action dated December 17, 2009. Applicant therefore respectfully requests that examination on the merits be commenced. It is believed that no additional fees are required, but in the event this is incorrect, please charge any additional fees required in connection with the present Response to Restriction Requirement and Amendment to Deposit Account No. 04-1133.

Respectfully submitted,

/Jennifer L. Livingston/
Jennifer L. Livingston
Reg. No. 56,404
1900 Chemed Center
255 East Fifth Street
Cincinnati, OH 45202
(513) 977-8359 (phone)
(513) 977-8141 (fax)